NEW YORK, NY--(Marketwire - December 02, 2010) - Kadmon Pharmaceuticals announced today that Three Rivers Pharmaceuticals, a Kadmon Company, has received approval from the US Food and Drug Administration (FDA) to market Topotecan Hydrochloride for Injection, 4 mg (base)/vial, the generic version of GlaxoSmithKline’s Hycamtin®. Kadmon’s Topotecan for Injection is now available for shipment.
Topotecan for Injection is indicated for small cell lung cancer sensitive disease after failure of first-line chemotherapy, and is also indicated for use in combination therapy with Cisplatin for stage IV-B, recurrent, or persistent carcinoma of the cervix not amenable to curative treatment with surgery and/or radiation therapy. Topotecan for Injection had U.S. sales of approximately $157.1 million in 2009, according to IMS Health.
“Topotecan for Injection is the second in a series of generic oncology products which Kadmon expects to market through its wholesale specialty pharmaceuticals sales network,” said Adriann Sax, Chief Commercial Officer of Kadmon Pharmaceuticals. “These generic products are part of an expanding commercial platform supporting Kadmon’s pipeline of pioneering, targeted medicines in oncology and other disease areas.”
About Kadmon Pharmaceuticals
Kadmon Pharmaceuticals LLC is a privately held, New York City-based biopharmaceutical company founded on its expertise in novel science. The company explores new understandings in molecular biology to develop therapies that target the metabolomic or signaling pathways associated with disease, including novel anti hepatitis C therapies. Collaborating with academic centers and private enterprise at the forefront of innovation, Kadmon is focused on pioneering medicines in the areas of oncology, infectious diseases and immunology.
Contact Information
For Kadmon Pharmaceuticals:
David Pitts
Argot Partners
212.600.1902
Email Contact
